Hva Skjer’a ?
Denne tråden er stengt for nye innlegg.
01.10.2021 kl 16:07
225000 aksjer omsatt før 09:10 på stigende priser på en «negativ børsdag»....
Her er det definitivt noe som skjer - stay tuned...
Her er det definitivt noe som skjer - stay tuned...
Redigert 15.09.2021 kl 17:36
Du må logge inn for å svare
Dette er direkte pinlig fra bergenbio sin side. Ingen info av noe slag..Hva driver de egentlig på med. Ny Ceo men hører ingen ting. Det er et hån mot oss aksjonærer. Bergenbio ta dokker i sammen. Basta.
BioBull
01.10.2021 kl 08:26
7496
Ja - pytt pytt - Det hadde vært deilig fremfor å sitte å irritere seg over nedgangen i aksjekurs… godt vi har helsa og humøret i behold ,- uansett utfall !
Redigert 01.10.2021 kl 08:27
Du må logge inn for å svare
Byzantin
01.10.2021 kl 08:51
7427
Er kursen nå så lav at selv store eiere/aksjonærer som Mohn (og familie) sitter med papirtap? Dere med litt fartstid i BgBio har kanskje en del kunnskap om dette.
Redigert 01.10.2021 kl 08:52
Du må logge inn for å svare
Hildebart
01.10.2021 kl 14:46
7115
Vi er nok med i kappløpet vi også, selv om vi ikke har trua for tida..
BioBull
01.10.2021 kl 15:24
7056
BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021
Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online from 10-14 November 2021.
Abstract titles have been announced online at the SITC website. Details of the presentation are below.
Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
Author: Rolf A. Brekken et al.
Abstract ID: 602
Full abstracts will be available on the SITC website beginning November 9th at 8:00 AM ET.
-Ends-
Contacts
Martin Olin,
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com
Rune Skeie,
Chief Financial Officer, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online from 10-14 November 2021.
Abstract titles have been announced online at the SITC website. Details of the presentation are below.
Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells
Author: Rolf A. Brekken et al.
Abstract ID: 602
Full abstracts will be available on the SITC website beginning November 9th at 8:00 AM ET.
-Ends-
Contacts
Martin Olin,
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com
Rune Skeie,
Chief Financial Officer, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700